Head to head
Vertex Pharmaceuticals vs Regeneron Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: VRTX · REGN
VRTX
Vertex Pharmaceuticals
515.02-1.08%
1-year price shape — +22% over the period
Quant Rating C · 62/100
vs
REGN
Regeneron Pharmaceuticals
920.69-0.19%
1-year price shape — +25% over the period
Quant Rating C · 71/100
1-year performance, rebased to 100
Regeneron Pharmaceuticals edges it on the scoreable measures. Regeneron Pharmaceuticals has the highest Quant Rating (71); Regeneron Pharmaceuticals has done best over the past year (+25%); Regeneron Pharmaceuticals trades cheapest on trailing earnings.
| VRTX | REGN | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | -- |
| Last price | 515.02 | 920.69 |
| Change today | -1.08% | -0.19% |
| 1-year return | +22.0% | +25.4% |
| Market cap | $130.58B | $95.24B |
| 52-week range | 412.27 – 568.67 | 590.23 – 990.72 |
| Valuation | ||
| P/E (TTM) | 33.14 | 20.35 |
| P/E percentile, own 5-yr range | 99th | 74th |
| P/B | 6.25 | 2.84 |
| Dividend yield | 0.00% | 0.40% |
| Profitability & growth | ||
| EPS (TTM) | 15.32 | 41.48 |
| Net profit (TTM) | $3.88B | $4.29B |
| Revenue (TTM) | $12.95B | $16.90B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +11.8% | +36.3% |
| Gross margin | 85.5% | 85.8% |
| Operating margin | 33.1% | 30.4% |
| Net margin | 30.7% | 28.5% |
| Free cash flow (TTM) | $3.20B | $3.63B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 96.8% | 90.9% |
| Insider activity (12mo) | 28 buy / 22 sell | 18 buy / 32 sell |
| Short interest (% of float) | 1.9% | 2.2% |
| Analyst consensus | 95% buy / 5% hold (21) | 70% buy / 30% hold (23) |
| Analyst price target | $624 (+21%) | $966 (+5%) |
| StockVane view | ||
| StockVane Quant Rating | C (62) | C (71) |
| Company | ||
| Employees | 6,400 | 15,410 |
| Founded | 1989 | 1988 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.